$STVN

Flynn Karen sold $26K of STVN

Flynn Karen sold 1,493 shares of Stevanato Group S.p.A. (STVN) at $17.09 on 2026-06-15.

Original reporting
SEC EDGAR · Flynn Karen
Published Jun 26, 2026, 10:05 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 26, 2026, 10:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$STVN
Neutral
high confidence
Mentioned
$STVN
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STVNNeutralLow
01

Why it matters

The newest fact is the director’s open-market sale details (shares, price, total value, post-transaction holdings).

02

Market read

Traders may note insider selling, but there is no accompanying fundamental update in the text to drive a durable repricing.

03

What to watch

Insider sales can be driven by diversification, tax, or pre-existing personal liquidity needs; the filing provides no stated rationale or linkage to company performance.

Relevance 3/10Novelty 3/10Timing: Filed 2026-06-26; sale occurred 2026-06-15.

Background

The article is an SEC Form 4 insider transaction disclosure for Stevanato Group S.p.A.

Company-level read

Ticker impact

$STVNNeutralHigh confidence
Context

Stevanato Group director Flynn Karen filed a Form 4 open-market sale of 1,493 shares at $17.09 on 2026-06-15.

Expected impact

Minimal near-term impact; any effect is likely short-lived and outweighed by normal trading noise.

Evidence & confidence

This is a standard Form 4 sale with no 10b5-1 plan and no accompanying company-specific operational or guidance change in the filing text.

Market effects

No sector-level read-across; single insider transaction without company guidance or regulatory/clinical updates.

None indicated.

None indicated.

Counterpoint

The absence of a 10b5-1 plan could be viewed as discretionary selling, but the disclosed size is small relative to typical institutional flows, limiting interpretability.

Key entities

  • Stevanato Group S.p.A.

    Subject of the Form 4 insider transaction; director Flynn Karen sold shares at $17.09.

  • Flynn Karen

    Director who executed the open-market sale; holdings after transaction reported as 5,757 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$STVNMedAI 8/10

Stevanato Group S.p.A. Q2 2026 Earnings Call Summary

Stevanato Group reported Q2 2026 revenue up 8%, with Biopharmaceutical and Diagnostic Solutions rising 9% and Engineering slightly down. High-value solutions grew 16% to 45% of revenue. Full-year 2026 guidance was raised to EUR 1.260-1.280 billion, citing a EUR 15 million Balda divestiture headwind. Alina variable dose pen received European regulatory approvals for liraglutide therapies.

$STVNMed

Stevanato (STVN) Q2 2026 Earnings Call Transcript

Stevanato Group (STVN) reported Q2 2026 revenue of EUR 302 million, up 8% year over year. High-value solutions rose 16% to EUR 135.9 million and were 45% of revenue. Gross margin increased 60 bps to 28.7%. Stevanato completed the sale of its California subsidiary Balda C. Brewer, recording EUR 12.2 million one-time expenses.

$STVNMed

Stevanato Group S.p.A. (STVN): Financial results for Q2 2026

Stevanato Group S.p.A. (STVN) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026 - The Company Divests its California-Based Subsidiary, Balda C. Brewer, Inc - (PIOMBINO DESE, Italy) – August 4, 2026 – Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of

$STVNMedAI 8/10

Stevanato Group S.p.A.: Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026

Stevanato Group (NYSE: STVN) reported Q2 fiscal 2026 revenue up 8% to €302.0m, with high-value solutions up 16% to €135.9m (45% of sales). Adjusted EBITDA margin rose to 26.0%. The company completed the sale of its California subsidiary Balda C. Brewer, incurring €12.2m expenses, and updated FY2026 guidance to revenue €1.260-€1.280b and adjusted EBITDA €335.0-€345.2m.